Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript

Operator

Welcome to the Enliven Therapeutics June 2026 Clinical Data Update. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Rick Fair, CEO of Enliven Therapeutics.

Richard Fair
CEO, President & Director

Greetings from EHA in Stockholm. Thank you all for joining us today. With me from Enliven are Helen Collins, our Chief Medical Officer; and Damiette Smit, our Vice President of Early Clinical Development. We’re also honored to be joined by Dr. Dennis Kim, Professor of Medicine in the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Center in Toronto. Dr. Kim will join us later in the call for Q&A.

On today’s call, we will be making forward-looking statements. These statements have risks. We encourage you to review our SEC filings for more information. Today, we are thrilled to provide important updates on our lead program, ELVN-001. We will provide an overview of the ELVN-001 opportunity and share exciting new clinical data from the ENABLE Phase I study that will be presented by Dr. Kim later today at the European Hematology Association meeting.

We will also provide an update on recent FDA interactions and next steps for the program. At the end of the call, we will open it up to the audience for a live Q&A. So please submit your questions any time during the call. Today’s data and regulatory updates reinforce our conviction that ELVN-001 has the potential to be the best-in-class tyrosine kinase inhibitor in CML.